August 3, 2017 – The U.S. Food and Drug Administration today approved Mavyret (glecaprevir and pibrentasvir) to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without…
Reader Survey
Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.